Clinical Trial Detail

NCT ID NCT01934894
Title Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SCRI Development Innovations, LLC
Indications

Her2-receptor positive breast cancer

Therapies

Cabazitaxel + Lapatinib

Age Groups: adult

Additional content available in CKB BOOST